Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0036572 (
seizures
)
80,221
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) is a condition that affects many parts of the body, particularly the brain and muscles. This study examined a Korean MELAS-like syndrome patient with
seizure
, stroke-like episode, and optic atrophy. Target sequencing of whole mtDNA and 73 nuclear genes identified compound heterozygous mutations p.R205X and p.L255P in the
FASTKD2
. Each of his unaffected parents has one of the two mutations, and both mutations were not found in 302 controls.
FASTKD2
encodes a FAS-activated serine-threonine (FAST) kinase domain 2 which locates in the mitochondrial inner compartment. A
FASTKD2
nonsense mutation was once reported as the cause of a recessive infantile mitochondrial encephalomyopathy. The present case showed relatively mild symptoms with a late onset age, compared to a previous patient with
FASTKD2
mutation, implicating an inter-allelic clinical heterogeneity. Because this study is the second report of an autosomal recessive mitochondrial encephalomyopathy patient with a
FASTKD2
mutation, it will extend the phenotypic spectrum of the
FASTKD2
mutation.
...
PMID:Identification of FASTKD2 compound heterozygous mutations as the underlying cause of autosomal recessive MELAS-like syndrome. 2849 82
Mutations in
FASTKD2
, a mitochondrial RNA binding protein, have been associated with mitochondrial encephalomyopathy with isolated complex IV deficiency. However, deficiencies related to other oxidative phosphorylation system (OXPHOS) complexes have not been reported. Here, we identified three novel
FASTKD2
mutations, c.808_809insTTTCAGTTTTG, homoplasmic mutation c.868C>T, and heteroplasmic mutation c.1859delT/c.868C>T, in patients with mitochondrial encephalomyopathy. Cell-based complementation assay revealed that these three
FASTKD2
mutations were pathogenic. Mitochondrial functional analysis revealed that mutations in
FASTKD2
impaired the mitochondrial function in patient-derived lymphocytes due to the deficiency in multi-OXPHOS complexes, whereas mitochondrial complex II remained unaffected. Consistent results were also found in human primary muscle cell and zebrafish with knockdown of
FASTKD2
. Furthermore, we discovered that
FASTKD2
mutation is not inherently associated with epileptic
seizures
, optic atrophy, and loss of visual function. Alternatively, a patient with
FASTKD2
mutation can show sinus tachycardia and hypertrophic cardiomyopathy, which was partially confirmed in zebrafish with knockdown of
FASTKD2
. In conclusion, both in vivo and in vitro studies suggest that loss of function mutation in
FASTKD2
is responsible for multi-OXPHOS complexes deficiency, and
FASTKD2
-associated mitochondrial disease has a high degree of clinical heterogenicity.
...
PMID:Mutations in FASTKD2 are associated with mitochondrial disease with multi-OXPHOS deficiency. 3194 55